Natalia Rompoti

16PUBLICATIONS
40CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMajor global burdens of diseasePredictive and prognostic markersAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 16, 2026
Drug survival of bimekizumab, guselkumab, and risankizumab after secondary IL-17 inhibitor failure.

|Jun 05, 2025
Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study.

Ioannis-Alexios Koumprentziotis, Irene Stefanaki, Natalia Rompoti

|Mar 29, 2025
Systemic inflammation correlates with depression and lower quality of life in patients with hidradenitis suppurativa independent of disease severity.

Nikolaos Rotsiamis, Natalia Rompoti, Aikaterini Liakou

|Feb 22, 2025
Risk of second primary cancers in patients with Merkel cell carcinoma: A systematic review and meta-analysis.

Ioannis-Alexios Koumprentziotis, Aikaterini Tsiogka, Natalia Rompoti

|Jan 17, 2025
Bimekizumab Treatment for Scalp Psoriasis: A 52-Week, Real-World, Retrospective Study.

Irene Stefanaki, Ioannis-Alexios Koumprentziotis, Natalia Rompoti

|Dec 31, 2024
Single-center experience with bimekizumab in psoriasis patients with previous exposure to interleukin-17 inhibitors.

Ioannis-Alexios Koumprentziotis, Natalia Rompoti, Irene Stefanaki

Pageof 3

Frequent Collaborators

6 joint publications

Electra Nicolaidou

5 joint publications

Ioannis-Alexios Koumprentziotis

4 joint publications

Evangelia Papadavid

4 joint publications

Irene Stefanaki